RxDoctor Payments Data

Marc Bloomenstein, OD

Optometrist · Scottsdale, AZNPI 1568428910

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $886,163 of the $1,365,153 with a category attached, or 64.9%. It is spread thinly across 32 manufacturers, the largest accounting for just 20.7%. 2025 is the largest year on record at $294,465, 2.3 times the $130,159 reported in 2019. Among optometrist clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,365,153in general payments, 2019–2025

Across 2,149 payments — averaging $635.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$283K
  • Sun Pharmaceutical Industries Inc.$231K
  • Bausch & Lomb Americas Inc.$202K
  • Tarsus Pharmaceuticals, Inc.$153K
  • Kala Pharmaceuticals, Inc.$115K
  • Oyster Point Pharma, Inc.$80K
  • plus $301K from 26 others
$903,327in research payments, 2019–2025

Across 65 payments — averaging $13,897 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sight Sciences, Inc.$529K
  • Oyster Point Pharma, Inc.$229K
  • Tarsus Pharmaceuticals, Inc.$134K
  • AbbVie$9K
  • Shire North American Group Inc$3K

What the payments were for

  • Consulting fees$303,44922%
  • Speaking & faculty fees$886,16365%
  • Travel & lodging$147,47311%
  • Food & beverage$28,0692%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,365,153 in reported general payments places this provider in the 95th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$65,392
Medicare patients
449
Services billed
604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj24$1,237,436
XdemvyLotilaner93$175,522
RestasisCyclosporine63$73,353
MieboPerfluorohexyloctane/Pf52$39,551
CequaCyclosporine33$26,788
XiidraLifitegrast21$21,455
Cyclosporine16$12,714
LumiganBimatoprost26$8,922
Prednisolone Acetate28$873
Latanoprost63$381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$48,382$1,237,43624 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$153,316$175,52293 claims
AbbVieRestasis, Lumigan$283,074$82,27689 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$202,461$61,00673 claims
Sun Pharmaceutical Industries Inc.Cequa$230,861$26,78833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →